Skip to content
‹ Back to IndustriesHealthcare

Encouraging the Adoption of Value-Based Care

How are Precision Health Insight Networks (PHINs) laying the groundwork for mainstream adoption of precision health? While recognized for its promise to save millions of lives and billions of dollars, the advancement of precision medicine has been limited to only a handful of conditions due to data silos and disconnected databases. The power of PHINs…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

·
Share

Free workspace

Turn your Healthcare expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

How are Precision Health Insight Networks (PHINs) laying the groundwork for mainstream adoption of precision health? While recognized for its promise to save millions of lives and billions of dollars, the advancement of precision medicine has been limited to only a handful of conditions due to data silos and disconnected databases.

The power of PHINs was on full display during COVID-19. Now, these award-winning solutions are poised to drive innovations across many disease states.

Brad Bostic, CEO of HC1, had this to say about the topic.

“So, I’ve been often asked the question about personalized medicine and the practical nature of that, and, ultimately, will it ever be mainstream?

My point of view on that is absolutely it will be. What I see happening right now within health care is this Renaissance that gives us a chance at getting there sooner rather than later.

The first part of that being the incentive models in healthcare, where, historically, we’ve been focused on a fee-for-service model. That incentivizes volume, and it doesn’t really allow for the idea of anything being personalized.

In fact, I’d say it’s quite the opposite. If you’re volume-motivated, you’re looking at it more like widgets. How do I do as much as I can, as fast as I can? And it’s not intended to deliver a bad outcome to patients, but there’s just not the right incentive there.

What we have emerging now is more of a value-based model.

We now know enough about how much it should cost to take care of different conditions. And, if you implement best practices to take care of those conditions and you effectively manage those patients, you can have a budget like a bucket of money per person in a given disease state or a given demographic within a population to care for them.

If you can do it in a way that costs less than what you were allocated, you can make more profit, so that’s creating an incentive. That’s clearing the way for programs that healthcare leaders are interested in investing in — precision healthcare types of models. A specific example of that would be the ability to truly identify those people in your population that are taking medications that aren’t working for them and doing that by looking at a combination of that person’s diagnosis, that person’s medication list, and that person’s specific genomic profile.

It’s something that I believe will become extremely widespread in the coming months and years. In fact, I once had the head of the health plan for one of the largest technology companies on earth say to me, in the next five years, it will be considered criminal negligence to not perform these precision prescribing kinds of tests like pharmacogenetics, and that was a very extreme statement.

But his point was, if we know we have a test that’s relatively low cost, that can determine what medication is going to work for you and prevent you from having a heart stent or potentially some kind of catastrophic cardiac arrest event. why would we allow that not to happen? Why would we not run that test to make sure that we’re getting you on the optimal medication? And that’s just one small example.

I think ultimately, though, what we’ll find is the kind of experience that we’ve grown to appreciate and expect from consumer services.”

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale

Facebook – facebook.com/marketscale

LinkedIn – linkedin.com/company/marketscale

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Book DemoSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Healthcare Insights

AHA and BD's 10-hospital pilot tests who acts on surgical blood pressure readings

AHA and BD's 10-hospital pilot tests who acts on surgical blood pressure readings

The American Hospital Association, West Health and BD will add continuous blood pressure monitoring to surgical care at 10 hospitals, with Vizient measuring results. The pilot tests the workflow around the device: who notices a change, who acts and who hands it off. Whether it spreads depends on cost after startup funding ends.

  • 01A monitor running in two operating rooms can support two different decisions, so device usage counts can say little about whether continuous blood pressure monitoring actually changed surgical care.
  • 02Hospitals evaluating continuous monitoring may already own idle devices; learning why they sit unused, whether training time or an awkward spot in the workflow, points to a different fix than a new purchase order.
  • 03A playbook is expected in roughly a year, aiming to define essential steps while leaving room for smaller or resource-limited hospitals—such as those without 24/7 pharmacy coverage—to adapt workflows locally.

Nov 19, 2026

Four renewal questions that can bring HbA1c closer to the dental chair

Four renewal questions that can bring HbA1c closer to the dental chair

Dr. Deepashree Rajendraprasad, a dentist turned hospital business intelligence developer, gives dental practices four questions for software vendors at contract renewal. They cover HL7 FHIR APIs, health information exchange access, SNODENT terminology and electronic referrals. The standards already exist. The payoff shows up chairside in anticoagulant screening, diabetes-guided periodontal care and bisphosphonate surgical planning.

  • 01Rajendraprasad argues that HbA1c is often already structured in medical systems; getting it to the dental chair starts with what a practice asks its software vendor.
  • 02Two of the five FHIR resources most relevant to dentistry, Patient and Observation, belong to the normative core of FHIR Release 4, where future changes are meant to stay backward compatible.
  • 03At renewal, ask vendors specifics: which FHIR resources they expose, whether they can query the regional HIE, whether they code in SNODENT, and whether they support structured referrals.

Nov 18, 2026

Johns Hopkins' Ritu Agarwal wants hospitals to measure a baseline before scaling AI

Johns Hopkins' Ritu Agarwal wants hospitals to measure a baseline before scaling AI

A Google Cloud survey found that only 30% of healthcare organizations have scaled advanced or agentic AI across their operations. Johns Hopkins professor Ritu Agarwal emphasizes the need for measured baselines, clinician-led design, and representative data for scaling, noting that pilots often hide key scaling insights.

  • 01A 200-person pilot answers whether a tool works; how it behaves on another hospital's patients and what it costs at full volume mostly show up after the pilot ends.
  • 02Just 30% of healthcare organizations said they’ve scaled advanced or agentic AI across operations, according to a Google Cloud survey of 250+ healthcare executives.
  • 03The sharper pre-pilot question: which disease condition and baseline metric will this tool be judged against?

Nov 18, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512